Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05668364
Other study ID # 2016-00845
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 1, 2016
Est. completion date May 31, 2021

Study information

Verified date January 2023
Source Pediatric Clinical Research Platform
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of the present randomised controlled clinical trial is to compare the efficacy of a 30-minute exposition to cold, atmospheric, outdoor air on the severity of croup symptoms with exposition to indoor room air in children with mild to moderate croup receiving a single dose of dexamethasone during winter croup outbreaks.


Description:

Croup is a viral laryngitis that represents the most common cause of acute upper airway obstruction in children. It is therefore a frequent reason for emergency department visits. The benefit of dexamethasone on croup symptoms is well established with an onset of action of at least 30 minutes. Various non-pharmacological measures, including exposition to cold air, are also thought to be effective in reducing the severity of symptoms, although this has not been demonstrated yet in the current scientific literature. The aim of the present study is to evaluate the efficacy of exposition to cold air on the symptoms of croup in children. The investigators designed a prospective, open-label, single centre randomised controlled trial to evaluate the effect of exposition to cold air on the symptoms of croup in children. The study was performed during autumn and winter croup outbreaks when outdoor air temperature was <10°C (<50°F). Participants were infants and children aged 3 months to 10 years presenting to the pediatric emergency department of our institution. Inclusion criteria were patients presenting with mild to moderate croup symptoms with Westley croup scores > or=2 (to permit a clinically relevant reduction in the Westley croup score of at least 2 points from baseline at 30 minutes), diagnosed by a triage nurse and confirmed by a senior attending pediatric emergency physician. Exclusion criteria were history or physical examination suggesting any other diagnosis, severe croup requiring immediate nebulised epinephrine, chronic respiratory disease (except asthma), underlying airway abnormalities, immunodeficiency; and contraindication to steroids. According to the recommended standards of care, all children with croup were administered a standard 0·6 mg/kg/dose oral dexamethasone at triage. Participants were randomly allocated either to the outdoor cold air exposition group or to the indoor group allocation using a single, constant 1:1 allocation ratio. Demographic data, previous exposition to cold air before presentation at pediatric emergency department, as well as vital signs and Westley croup score on arrival, and after 30 and 60 minutes, were recorded. Parents were reached by phone 7 days after the initial visit to assess the child's clinical outcome and the final diagnosis, as well as the need for further consultation or hospitalization in the meantime.


Recruitment information / eligibility

Status Completed
Enrollment 118
Est. completion date May 31, 2021
Est. primary completion date May 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Months to 10 Years
Eligibility Inclusion Criteria: - children from 3 months to 10 years with clinical signs of croup and Westley croup score > or =2 Exclusion Criteria: - Need for close monitoring - Need for nebulized epinephrine - History or physical examination suggesting any other diagnosis - Chronic respiratory disease (except asthma) - Underlying airway abnormalities - Immunodeficiency - Contraindication to steroids

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Outdoor cold air exposure
Exposure to outdoor cold air (<10°C or <50°F, intervention group) for 30 minutes. On completion of the intervention, participants remained under observation at indoor ambient air from 30 minutes to 60 minutes from the intervention.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Pediatric Clinical Research Platform

References & Publications (5)

Bjornson CL, Williamson J, Johnson DW. Telephone Out Patient Score: The Derivation and Validation of a Telephone Follow-up Assessment Tool for Use in Clinical Research in Children With Croup. Pediatr Emerg Care. 2016 May;32(5):290-7. doi: 10.1097/PEC.0000 — View Citation

Gates A, Gates M, Vandermeer B, Johnson C, Hartling L, Johnson DW, Klassen TP. Glucocorticoids for croup in children. Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD001955. doi: 10.1002/14651858.CD001955.pub4. — View Citation

Hanna J, Brauer PR, Morse E, Berson E, Mehra S. Epidemiological analysis of croup in the emergency department using two national datasets. Int J Pediatr Otorhinolaryngol. 2019 Nov;126:109641. doi: 10.1016/j.ijporl.2019.109641. Epub 2019 Aug 13. — View Citation

Johnson DW. Croup. BMJ Clin Evid. 2014 Sep 29;2014:0321. — View Citation

Moore M, Little P. Humidified air inhalation for treating croup. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002870. doi: 10.1002/14651858.CD002870.pub2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Westley croup score at 30 minutes The primary outcome is the proportion of patients showing an decrease of at least 2 points in their Westley croup score at 30 minutes from triage.
The 5-item Westley croup score uses a 17 points ordinal scale to assess level of consciousness (5 points), cyanosis (5 points), stridor (2 points), air entry (2 points), and chest wall retractions (3 points). Mild croup is defined as a WCS < or = 2, moderate 3-5, severe 6-11, and impending respiratory failure or >12.
at 30 minutes
Secondary Westley croup score at 60 minutes The secondary outcome is the proportion of patients showing an decrease of at least 2 points in their Westley croup score at 60 minutes from triage.
The 5-item Westley croup score uses a 17 points ordinal scale to assess level of consciousness (5 points), cyanosis (5 points), stridor (2 points), air entry (2 points), and chest wall retractions (3 points). Mild croup is defined as a WCS < or = 2, moderate 3-5, severe 6-11, and impending respiratory failure or >12.
at 60 minutes
Secondary Pulse oxymetry Pulse oxymetry in % at 0 min, at 30 and at 60 minutes from enrolment at triage
Secondary Respiratory rate Respiratory rate in breaths/min at 0 min, at 30 and at 60 minutes from enrolment at triage
Secondary Heart rate Heart rate in beats/min at 0 min, at 30 and at 60 minutes from enrolment at triage
Secondary Telephone Outpatient derived score Anamnestic scoring tool to estimate croup severity, derived from the original Telephone Out Patient score at the time of leaving home for the pediatric emergency department visit; at 0 min on pediatric emergency department arrival (i.e., at triage); at day 7 from the initial visit
Secondary Hospitalisation rate Rate of hospital admission for croup Within 7 days from the initial visit
Secondary Adverse events Parental or patient perception of adverse events related to exposure to outdoor cold air. at 30 minutes from enrolment at triage
See also
  Status Clinical Trial Phase
Terminated NCT01748162 - Management of Recurrent Croup Phase 3
Completed NCT00230841 - Comparing Different Ways of Delivering Humidity to Children With Croup Phase 2
Terminated NCT00147849 - A Cluster Controlled Trial Comparing Three Methods of Disseminating Practice Guidelines for Children With Croup N/A
Terminated NCT03705273 - Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup Phase 4
Completed NCT01042145 - Community Care for Croup (RCT) Phase 4
Completed NCT00368823 - A Trial of Point of Care Information in Ambulatory Pediatrics Phase 3
Not yet recruiting NCT06272383 - Croup Dosing Study Phase 1
Completed NCT03392363 - Diagnosing Respiratory Disease in Children Using Cough Sounds 2
Recruiting NCT01664507 - The Effect and Safety of Low Dose Nebulized Epinephrine in Croup Phase 4
Completed NCT06156436 - A Study Evaluating the Use of ResAppDx v2.0 as an Aid to Diagnose Respiratory Disease in Paediatric Patients in an Emergency Department
Not yet recruiting NCT04168554 - Telemedicine in the Generals Practitioners Office
Completed NCT02973282 - Diagnosing Respiratory Disease in Children Using Cough Sounds N/A
Terminated NCT00938353 - Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup Phase 3